Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sanofi
Biotech
Sanofi scraps Nurix program 2 months after entering clinic
Sanofi has decided to end work on a STAT6 degrader from Nurix just two months after taking the inflammatory disease drug into the clinic.
James Waldron
Nov 4, 2026 5:02am
Sanofi mulling ‘moonshot’ M&A targets to survive Dupixent cliff
Oct 30, 2026 3:27am
Sanofi pays Regeneron $1B for 4 early-stage assets to ignite R&D
Oct 1, 2026 4:24am
Owkin, Servier ink oncology trial and discovery deal
Sep 11, 2026 2:01pm
A year after Big Pharma’s pull-back from the UK, what’s changed?
Sep 4, 2026 10:00am
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
Aug 31, 2026 11:27am
